If you enjoy this content, please share it with a colleague
ViewRay Incorporated
RELATED CONTENT
September 17, 2014 — ViewRay announced the world’s first on-table adaptive radiation treatment program using the MRIdian system began at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis. The MRIdian system provides a patented combination of continuous magnetic resonance imaging (MRI) and simultaneous radiation therapy delivery for the treatment of cancer.
The MRIdian system from ViewRay is now being used to treat patients at the University of Wisconsin Carbone Cancer Center in Madison, Wis., the second clinical group in the world to treat patients with magnetic resonance imaging (MRI)-guided radiation therapy.
July 30, 2014 — ViewRay featured its MRIdian system at the 2014 annual meeting of the American Association of Physicists in Medicine (AAPM), held in Austin, Texas.
The ViewRay system, a MRI-guided radiation therapy system, is being used to treat patients at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, Mo. The ViewRay system provides a combination of simultaneous radiation therapy delivery and continuous magnetic resonance imaging (MRI) for the treatment of cancer.
ViewRay Inc., a privately held medical device company, secured $30 million of funds to support the worldwide commercialization of the ViewRay system.
May 30, 2012 — ViewRay Inc., a privately held medical device company, has received U.S. Food and Drug Administration (FDA) 510(k) premarket notification clearance for its magnetic resonance guided (MRI)-guided radiation therapy system. The ViewRay system features a unique combination of radiotherapy delivery and simultaneous MRI for the treatment of cancer. ViewRay's treatment planning and delivery software received 510(k) premarket notification clearance in 2011.
March 14, 2012 — ViewRay said it received $45 million in new financing to help speed development of its magnetic resonance imaging (MRI) image-guided radiation therapy (IGRT) system.
September 30, 2011 – ViewRay Inc. will present potential applications for magnetic resonance imaging (MRI)-guided radiotherapy at the annual meeting of the American Society for Radiation Oncology (ASTRO) Oct. 2-4 in Miami Beach, Fla., with software demonstrations in booth #865. The company's new research radiation therapy system is being developed to feature a patented combination of radiotherapy delivery and simultaneous magnetic resonance imaging (MRI). The system is being designed to let radiation oncologists see what they're treating, while they're treating.
May 23, 2011 - The core technology of ViewRay Inc., a combination of magnetic resonance imaging (MRI) and radiotherapy technologies, has been issued landmark patents in the United States and Europe. ViewRay, a privately held medical device company, holds the exclusive worldwide license for the technology from the University of Florida. The cancer treatment technology was invented by company founder James F. Dempsey, Ph.D., while he was a member of the radiation oncology faculty at the University of Florida.
March 14, 2011 – The University of Wisconsin Carbone Cancer Center (UWCCC) in Madison, Wis., will soon become one of the first oncology research centers to acquire a radiotherapy system from ViewRay. The research radiation therapy system features a combination of radiotherapy delivery and simultaneous magnetic resonance imaging (MRI).